title: Evolving directions in obesity management.
abstract: Over the past decade, treatment for obesity has been limited because of an incomplete understanding of the pathophysiology of obesity, lack of recognition of it as a disease, and limited efficacy of treatment options. Safety concerns related to medical and surgical approaches for obesity have also been a major barrier. The challenging nature of obesity management is reflected in a survey of primary care physicians which indicated that treating patients with obesity can be as difficult as treating patients with nicotine or alcohol dependence.
authors.affiliation: Weill Cornell Medical College Medical Director, Center for Weight Management and Metabolic Clinical Research, New York, NY, USA.
authors.forename: Louis J
authors.initials: LJ
authors.lastname: Aronne
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D005544:Forecasting; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D054795:Incretins / Q000627:therapeutic use; D000069450:Liraglutide; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D009765:Obesity / Q000517:prevention & control*; D018027:Receptors, Glucagon / Q000819:agonists
chemical_list: D019440:Anti-Obesity Agents; D018765:Dopamine Uptake Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D054795:Incretins; D009292:Narcotic Antagonists; D018027:Receptors, Glucagon; D016642:Bupropion; D009271:Naltrexone; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1